Fertility, pregnancy planning, and pharmacotherapy during the pregnancy, postpartum and breastfeeding period in patients with rheumatoid arthritis and other inflammatory arthropathies

Marzena Olesińska1, Lidia Ostanek2, Maria Majdan3, Mariola Kosowicz4, Justyna Teliga-Czajkowska5, Piotr Wiland6 1Klinika i Poliklinika Układowych Chorób Tkanki Łącznej Instytutu Reumatologii im. prof. dr hab. med. Eleonory Reicher w Warszawie 2Klinika Reumatologii i Chorób Wewnętrznych Pomorskiego Uniwersytetu Medycznego w Szczecinie 3Katedra i Klinika Reumatologii i Układowych Chorób Tkanki Łącznej Uniwersytetu Medycznego w Lublinie 4Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie w Warszawie 5Zakład Dydaktyki Ginekologiczno-Położniczej Warszawskiego Uniwersytetu Medycznego 6Katedra i Klinika Reumatologii i Chorób Wewnętrznych Uniwersytetu Medycznego we Wrocławiu 1Department and Polyclinic of Connective Tissue Diseases, Institute of Rheumatology in Warsaw 2Department of Rheumatology and Internal Diseases, Pomeranian Medical University in Szczecin 3Chair and Department of Rheumatology and Systemic Connective Tissue Diseases, Medical University of Lublin 4Centre of Oncology, Maria Skłodowska-Curie Institute in Warsaw 5Gynaecology and Obstetrics Didactic Division, Warsaw Medical University 6Chair and Department of Rheumatology and Internal Diseases, Medical University of Wrocław

[1]  A. Tincani,et al.  Antirheumatic drugs and reproduction in women and men with chronic arthritis , 2015, RMD Open.

[2]  F. Förger,et al.  How safe are anti-rheumatic drugs during pregnancy? , 2013, Current opinion in pharmacology.

[3]  M. Dubinsky,et al.  Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  C. Bombardier,et al.  Safety of Pain Therapy During Pregnancy and Lactation in Patients with Inflammatory Arthritis: A Systematic Literature Review , 2012, Journal of Rheumatology Supplement.

[5]  R. Xu,et al.  Pregnancy outcome in women exposed to leflunomide before or during pregnancy. , 2012, Arthritis and rheumatism.

[6]  K. Michaud,et al.  Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus , 2012, Arthritis care & research.

[7]  A. Scialli,et al.  Teratogen update: methotrexate. , 2012, Birth defects research. Part A, Clinical and molecular teratology.

[8]  M. Clementi,et al.  Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services , 2012, American journal of medical genetics. Part A.

[9]  D. Wilkinson.  Fatal fetal paternalism , 2012, Journal of Medical Ethics.

[10]  F. Chervenak,et al.  Responsibly counselling women about the clinical management of pregnancies complicated by severe fetal anomalies , 2012, Journal of Medical Ethics.

[11]  J. Olsen,et al.  Time to pregnancy among women with rheumatoid arthritis. , 2011, Arthritis and rheumatism.

[12]  K. Salvesen,et al.  Pregnancy and delivery in women with chronic inflammatory arthritides with a specific focus on first birth. , 2011, Arthritis and rheumatism.

[13]  T. Farragher,et al.  Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis Register , 2011, Annals of the rheumatic diseases.

[14]  E. Chakravarty,et al.  Pregnancy outcomes after maternal exposure to rituximab. , 2011, Blood.

[15]  E. Bonfá,et al.  Maintenance of fertility in patients with rheumatic diseases needing antiinflammatory and immunosuppressive drugs , 2010, Arthritis care & research.

[16]  M. Clowse.  The use of anti-TNFα medications for rheumatologic disease in pregnancy , 2010, International journal of women's health.

[17]  R. Xu,et al.  Birth outcomes in women who have taken leflunomide during pregnancy. , 2010, Arthritis and rheumatism.

[18]  P. Alba,et al.  [Treat to target in rheumatoid arthritis]. , 2010, Revista de la Facultad de Ciencias Medicas.

[19]  L. Carmona,et al.  Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). , 2009, Clinical and experimental rheumatology.

[20]  A. Mitchell,et al.  Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature , 2009, American journal of medical genetics. Part A.

[21]  G. T. V. van Well,et al.  Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development , 2008, Clinical & developmental immunology.

[22]  C. Gordon,et al.  Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. , 2008, Rheumatology.

[23]  Richard S. Lee,et al.  Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[24]  C. Rochlitz,et al.  Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. , 2006, The Lancet. Oncology.

[25]  B. Drénou,et al.  Administration of rituximab during the first trimester of pregnancy without consequences for the newborn , 2006, Journal of Perinatology.

[26]  N. Schmitz,et al.  The effects of rituximab treatment during pregnancy on a neonate. , 2006, Haematologica.

[27]  E. Kimby,et al.  Safety of rituximab therapy during the first trimester of pregnancy: a case history , 2004, European journal of haematology.

[28]  M. D'armiento,et al.  Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. , 2004, Birth defects research. Part A, Clinical and molecular teratology.

[29]  K. Jones,et al.  Cyclophosphamide, methotrexate, and cytarabine embropathy: is apoptosis the common pathway? , 2003, Birth defects research. Part A, Clinical and molecular teratology.

[30]  R. Brent.  Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. , 2001, Teratology.

[31]  M. Herold,et al.  Efficacy and safety of a combined rituximab chemotherapy during pregnancy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Roeder,et al.  Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? , 1999, American journal of medical genetics.

[33]  L. Buckley,et al.  Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. , 1997, Arthritis and rheumatism.

[34]  G. Koren,et al.  Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. , 1993, Teratogenesis, carcinogenesis, and mutagenesis.

[35]  G. Koren,et al.  Fetal outcome after in utero exposure to cancer chemotherapy. , 1992, Archives of internal medicine.

[36]  Bob Barger.  Transfer of Drugs and Other Chemicals into Human Milk , 1990 .

[37]  E. McCabe,et al.  TERATOGENIC EFFECTS OF FIRST‐TRIMESTER CYCLOPHOSPHAMIDE THERAPY , 1988, Obstetrics and gynecology.

[38]  D. Gershenson.  Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Mirkes.  Cyclophosphamide teratogenesis: a review. , 1985, Teratogenesis, carcinogenesis, and mutagenesis.

[40]  J. Reichert,et al.  Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. A case report. , 1984, JAMA.

[41]  J. Durodola.  Administration of cyclophosphamide during late pregnancy and early lactation: a case report. , 1979, Journal of the National Medical Association.

[42]  R. H. Moser,et al.  Fetal effects during cyclophosphamide and irradiation therapy. , 1971, Annals of internal medicine.

[43]  L. H. Greenberg,et al.  CONGENITAL ANOMALIES PROBABLY INDUCED BY CYCLOPHOSPHAMIDE. , 1964, JAMA.